Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

17.43 (USD) • At close June 27, 2025
Bedrijfsnaam Apellis Pharmaceuticals, Inc.
Symbool APLS
Munteenheid USD
Prijs 17.43
Beurswaarde 2,190,637,260
Dividendpercentage 0%
52-weken bereik 16.1 - 42.47
Industrie Biotechnology
Sector Healthcare
CEO Dr. Cedric Francois M.D., Ph.D.
Website https://www.apellis.com

An error occurred while fetching data.

Over Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA)

Vergelijkbare Aandelen

The Ensign Group, Inc. logo

The Ensign Group, Inc.

ENSG

153.35 USD

Medpace Holdings, Inc. logo

Medpace Holdings, Inc.

MEDP

310.69 USD

Tandem Diabetes Care, Inc. logo

Tandem Diabetes Care, Inc.

TNDM

18.94 USD

Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

LNTH

81.49 USD

ICU Medical, Inc. logo

ICU Medical, Inc.

ICUI

131.82 USD

Premier, Inc. logo

Premier, Inc.

PINC

21.61 USD

QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

28.87 USD

Alkermes plc logo

Alkermes plc

ALKS

28.81 USD

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

47.49 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)